Enter your login e-mail to the account
Search
Search parameters
Search results
- Biologics for rheumatoid arthritis treatment
prof. MUDr. Juraj Payer, CSc., MUDr. Daniel Čierny, doc. MUDr. Zdenko Killinger, PhD., MUDr. Kristína Brázdilová
(9/2009, Review articles )
- Role of T and B cells in pathogenesis of multiple sclerosis
prof. RNDr. Jan Krejsek, CSc., doc. MUDr. Martin Vališ, Ph.D., MUDr. Zbyšek Pavelek
(2/2016, Review articles ) - The use of monoclonal antibodies in neurology
prof. MUDr. Egon Kurča, PhD., MUDr. Mária Cuninková
(6/2011, Main topic ) - High efficacy treatment since the first attack – an important step in the treatment of multiple sclerosis?
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(1/2023, Review articles ) - Ocrelizumab – pharmacoloical profile
doc. MUDr. Radomír Taláb, CSc., MUDr. Marika Talábová
(5/2018, Pharmacotherapy ) - Monoklonální protilátky v léčbě roztroušené sklerózy
MUDr. Marek Peterka , MUDr. Zdeněk Kasl, Ph.D.
(2/2018, Pharmacotherapy ) - Biological therapy by Ocrelizumab (antiCD20) is surprisingly clinically effective in multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2017, From the boundary of neurology ) - Ocrelizumab is dampening the harm inflammation in patients with multiple sclerosis with little impact on protective immunity
prof. RNDr. Jan Krejsek, CSc.
(3/2020, From the boundary of neurology ) - B lymfocyty v roztroušené skleróze mozkomíšní a postavení biologika cílícího na B lymfocyty v její léčbě
prof. RNDr. Jan Krejsek, CSc.
(3/2018, From the boundary of neurology ) - Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2022, From the boundary of neurology ) - Ocrelizumab v léčbě roztroušené sklerózy
Prof. MUDr. Eva Kubala Havrdová, CSc.
(4/2017, Pharmacotherapy )